Trial Profile
Phase Ib/II Investigator Sponsored Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax in IDH1-Mutated Hematologic Malignancies
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 28 Nov 2023
Price :
$35
*
At a glance
- Drugs Ivosidenib (Primary) ; Venetoclax (Primary) ; Azacitidine; Azacitidine
- Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 21 Nov 2023 Planned number of patients changed from 30 to 96.
- 15 Aug 2023 Planned End Date changed from 30 Sep 2023 to 30 Sep 2025.
- 15 Aug 2023 Planned primary completion date changed from 30 Sep 2023 to 30 Sep 2025.